INOVIQ LTD — M&A Activity 2020

Jul 19, 2020

==> picture [125 x 48] intentionally omitted <==

ASX RELEASE

Court Approves Scheme of Arrangement

Melbourne, Australia, 20 July 2020: The Federal Court of Australia today ordered that the Scheme of

Arrangement ( Scheme ) between Sienna Cancer Diagnostics Limited (ASX: SDX) (“Sienna” or “the Company”) and its shareholders in relation to the proposed acquisition of all the shares in Sienna by BARD1 Life Sciences Limited ( BARD1 ) be approved.

The Scheme was approved by Sienna shareholders at the Scheme Meeting held on Wednesday, 15 July 2020. The Scheme will become effective once a copy of the Court order is lodged with the Australian Securities and Investments Commission ( ASIC ).

Sienna proposes to lodge the Court order approving the Scheme with ASIC and ASX on 20 July 2020. Following the lodgement of the Court order, it is expected that 395,132,839 shares will be suspended from the close of trading on the ASX on 20 July 2020.

ENDS.

For Further Information, please contact: Carl Stubbings, CEO & Managing Director Sienna Cancer Diagnostics Ltd cstubbings@siennadiagnostics.com.au +61 3 9548 7586

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna’s first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a “Molecular Net” technology called SIEN-NET[TM] . The first commercial embodiment of SIEN-NET is EXO-NET[TM] , which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.